T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
T2 Biosystems (NASDAQ: TTOO) has extended its capital equipment supplier agreement with Vizient, Inc. through March 31, 2026. The agreement covers the T2Dx® Instrument, T2Bacteria® Panel, and T2Candida® Panel - the only FDA-cleared products for detecting sepsis-causing pathogens directly from whole blood.
Vizient, the largest member-driven healthcare performance improvement company in the US, serves organizations representing approximately $140 billion in annual purchasing volume, including over 65% of acute care hospitals and 97% of academic medical centers. The extension provides Vizient members continued access to contracted pricing and broader exposure to T2 Biosystems' diagnostic technology.
T2 Biosystems (NASDAQ: TTOO) ha esteso il suo accordo di fornitura di attrezzature di capitali con Vizient, Inc. fino al 31 marzo 2026. L'accordo copre il T2Dx® Instrument, il T2Bacteria® Panel e il T2Candida® Panel - i soli prodotti approvati dalla FDA per rilevare i patogeni che causano sepsi direttamente dal sangue intero.
Vizient, la più grande azienda americana di miglioramento delle performance sanitarie guidata da membri, serve organizzazioni che rappresentano circa 140 miliardi di dollari in volume di acquisti annuali, inclusi oltre il 65% degli ospedali di emergenza e il 97% dei centri medici accademici. L'estensione offre ai membri di Vizient un accesso continuato a prezzi contrattati e una maggiore esposizione alla tecnologia diagnostica di T2 Biosystems.
T2 Biosystems (NASDAQ: TTOO) ha ampliado su acuerdo de suministro de equipos de capital con Vizient, Inc. hasta el 31 de marzo de 2026. El acuerdo abarca el T2Dx® Instrument, el T2Bacteria® Panel y el T2Candida® Panel - los únicos productos autorizados por la FDA para detectar patógenos que causan sepsis directamente desde sangre entera.
Vizient, la empresa más grande de mejora del rendimiento en salud impulsada por miembros en los EE. UU., sirve a organizaciones que representan aproximadamente 140 mil millones de dólares en volumen de compras anuales, incluyendo más del 65% de los hospitales de cuidados agudos y el 97% de los centros médicos académicos. La extensión proporciona a los miembros de Vizient acceso continuo a precios contractuales y una mayor exposición a la tecnología diagnóstica de T2 Biosystems.
T2 바이오시스템즈 (NASDAQ: TTOO)는 비지언트, Inc.와의 자본 장비 공급 계약을 2026년 3월 31일까지 연장했습니다. 이 계약은 T2Dx® 기기, T2Bacteria® 패널, T2Candida® 패널을 포함하며, 이는 전체 혈액에서 직접 패혈증 유발 병원체를 감지하기 위해 FDA에서 승인한 유일한 제품입니다.
비지언트는 미국 최대의 회원 기반 의료 성과 향상 회사로, 연간 구매량 약 1400억 달러에 해당하는 조직을 지원하며, 급성 치료 병원의 65% 이상 및 학술 의료 센터의 97%를 포함합니다. 이번 연장은 비지언트 회원들에게 계약된 가격에 대한 지속적인 접근과 T2 바이오시스템즈의 진단 기술에 대한 더 넓은 노출을 제공합니다.
T2 Biosystems (NASDAQ: TTOO) a prolongé son accord de fourniture d'équipements de capital avec Vizient, Inc. jusqu'au 31 mars 2026. L'accord couvre l'instrument T2Dx®, le panneau T2Bacteria® et le panneau T2Candida® - les seuls produits approuvés par la FDA pour détecter directement les pathogènes causant la sepsis à partir de sang total.
Vizient, la plus grande entreprise américaine d'amélioration de la performance en santé basée sur les membres, sert des organisations représentant environ 140 milliards de dollars de volume d'achats annuels, y compris plus de 65 % des hôpitaux de soins aigus et 97 % des centres médicaux académiques. La prolongation offre aux membres de Vizient un accès continu à des prix contractuels et une plus grande exposition à la technologie diagnostique de T2 Biosystems.
T2 Biosystems (NASDAQ: TTOO) hat seine Vereinbarung über die Lieferung von Kapitalgeräten mit Vizient, Inc. bis zum 31. März 2026 verlängert. Die Vereinbarung umfasst das T2Dx® Instrument, das T2Bacteria® Panel und das T2Candida® Panel - die einzigen von der FDA zugelassenen Produkte zur direkten Erkennung von sepsisverursachenden Krankheitserregern aus Vollblut.
Vizient, das größte mitgliedergetriebene Unternehmen zur Verbesserung der Gesundheitsleistung in den USA, bedient Organisationen, die etwa 140 Milliarden Dollar an jährlichem Einkaufsvolumen repräsentieren, darunter über 65% der Akutkrankenhäuser und 97% der akademischen medizinischen Zentren. Die Verlängerung bietet den Mitgliedern von Vizient weiterhin Zugang zu vertraglich festgelegten Preisen und eine breitere Bekanntheit der diagnostischen Technologie von T2 Biosystems.
- Extended partnership with largest US healthcare GPO (Vizient) through March 2026
- Access to Vizient's network representing $140B in annual purchasing volume
- Maintains contracted pricing for FDA-cleared sepsis detection products
- Exposure to 65% of US acute care hospitals and 97% of academic medical centers
- None.
Insights
The extension of T2 Biosystems' supplier agreement with Vizient is strategically significant but comes with measured expectations given TTOO's micro-cap status. Vizient's massive
The agreement's focus on T2's FDA-cleared sepsis detection platform maintains their competitive positioning in the critical rapid diagnostics market. The extension through 2026 provides important revenue visibility and stability for their capital equipment sales pipeline. Yet, historical adoption rates and TTOO's current market cap suggest cautious expectations about near-term sales acceleration despite the valuable channel access.
The contract extension preserves T2's access to a important distribution channel for their differentiated sepsis diagnostic technology. Their direct-from-blood testing capability addresses a critical clinical need for rapid pathogen detection, which can significantly impact patient outcomes in sepsis cases where time-to-treatment is vital. The continued partnership with Vizient validates the clinical utility of their platform.
However, the
LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2026. The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bacteria® Panel and the T2Candida® Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood.
“We are pleased to extend our multi-year agreement with Vizient, the nation’s largest group purchasing organization. This reiterates the continued value that our products offer to patients suspected of sepsis,” stated John Sperzel, Chairman and CEO of T2 Biosystems. “We believe there is a strong need for hospitals to have more effective and direct-from-blood rapid diagnostics that enable faster targeted antimicrobial treatment and this Vizient extension provides hospitals with greater access to our life-saving technology.”
Through the extended contract, Vizient members will continue to have access to broader exposure and contracted pricing for the T2Dx® Instrument, the T2Bacteria® Panel and the T2Candida® Panel, the only FDA-cleared products able to detect sepsis-causing pathogens directly from whole blood.
Vizient serves a wide range of health care organizations that represent a combined purchasing volume of approximately
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology and include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2Biothreat™ Panel. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the T2Lyme™ Panel, and the expended T2Candida Panel to add the detection of Candida auris. For more information, please visit www.t2biosystems.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the likelihood that the extension of the multi-year agreement will result in greater hospital access to T2 Biosystems’ products; and all other statements that include the words “expect,” “may,” “should,” “anticipate,” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, or SEC, on April 1, 2024, and other filings the Company makes with the SEC from time to time, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406
FAQ
When does T2 Biosystems' (TTOO) extended agreement with Vizient expire?
What products are covered under T2 Biosystems' (TTOO) Vizient agreement?
What percentage of US acute care hospitals can access TTOO products through the Vizient agreement?
What is the annual purchasing volume of healthcare organizations served by Vizient?